Navigation Links
Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
Date:10/19/2010

ssed or implied in this press release due to a number of risks and uncertainties, including the risk that BYDUREON may not be approved by the FDA as soon as anticipated or at all; the companies' response to the complete response letter may not be submitted in a timely manner and/or the information provided in such response may not satisfy the FDA; the FDA may request additional information prior to approval; BYETTA and/or the approval of BYDUREON and the revenues generated from these products may be affected by competition; unexpected new data; safety and technical issues; clinical trials not being completed in a timely manner, not confirming previous results, not being predictive of real world use or not achieving the intended clinical endpoints; label expansion requests or NDA filings not receiving regulatory approval; the commercial launch of BYDUREON being delayed; or manufacturing and supply issues. The potential for BYETTA and/or BYDUREON may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products including those inherent in the collaboration with and dependence upon Amylin, Lilly and/or Alkermes. These and additional risks and uncertainties are described more fully in Amylin's, Lilly's and Alkermes' most recent SEC filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin, Lilly and Alkermes undertake no duty to update these forward-looking statements.

BYDUREON™ and BYETTA® are trademarks of Amylin Pharmaceuticals, Inc., and Medisorb® is a registered trademark of Alkermes, Inc. 

P-LLY

(i)The International Diabetes Federation Diabetes Atlas. Available at:

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... the acquisition of leading OTC brands from GSK in ... transaction is a clear demonstration of Perrigo,s unique ability ... distribution network spanning 36 countries.  Perrigo ... commented, "We are excited to complete this transaction, which ...
(Date:8/28/2015)... Massachusetts y LONDRES, 28 de agosto ... AEX: PHIA) anunció hoy su participación en el  ... exhibirá sus soluciones cardiológicas más recientes y novedosas, ... Cardiovascular, que conectan a las personas y la ... de ayudar a diagnosticar, guiar los tratamientos y ...
(Date:8/27/2015)... DURECT Corporation (Nasdaq: DRRX ) announced ... upcoming healthcare conferences.  , James ... the Rodman & Renshaw Investment Conference on Thursday, September ... being held at the St. Regis Hotel in ... webcast of the presentation will be available by accessing ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5DURECT to Participate in Upcoming Healthcare Conferences 2
... , ALLEGAN, Mich., Nov. 19 Perrigo Company ... and CEO Joseph C. Papa will present at the Sidoti ... (EST) at the Grand Hyatt Hotel in New York City. ... supplier that develops, manufactures and distributes OTC and prescription pharmaceuticals, ...
... Nov. 19 Delcath Systems, Inc. (Nasdaq: DCTH ), ... (PHP(TM)) System, a minimally invasive drug delivery platform for the ... on the Company,s recent progress. , "Since we last communicated ... many significant milestones as we move into the first regulatory ...
Cached Medicine Technology:Delcath Systems Reports Substantial Progress 2Delcath Systems Reports Substantial Progress 3Delcath Systems Reports Substantial Progress 4
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, ... the treatment of prostate cancer, has announced the roll-out of its newest technology ... center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at ...
(Date:8/29/2015)... ... 30, 2015 , ... On September 30, 2015, the Career and Transfer Center ... accredited Maricopa Community Colleges , will be hosting a Job Expo to provide ... and opportunities. , The Expo has expanded to much more than just a typical ...
(Date:8/29/2015)... ... , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of Policy ... present an educational program titled “Asbestos and Your Health.” , The two and one ... at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA 19002. ...
(Date:8/29/2015)... ... August 29, 2015 , ... It can be ... against dribbled urine and sweat. "In order to prevent these problems, I conceived ... ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a male’s crotch. It ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... Dr. Tim ... mission. His mission is to increase acceptance of the chiropractic field in the ... that further debilitate them. Although Chiropractic was made available to the VA program ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
... supplements containing the mycoestrogen zearalenone (ZEN), a naturally occurring ... their risk of breast cancer. That is the warning ... ahead of print publication in the January issue of ... Practice . "No clinical trials have been published ...
... Australia, cancer incidence rates have increased while deaths from cancer ... a recent study published early online in the Asia-Pacific ... disease group, cancer has the greatest overall impact on Australians, ... in five dying from it before the age of 85. ...
... early-stage HER2-positive breast cancer may have worse ... Mayo Clinic researchers found in a study presented today ... Symposium . HER2-positive breast cancer gets its name from ... that promotes cancer cell growth. "Not only did ...
... the results of a new study published in the ... African-Americans, Hispanics and uninsured patients use fewer post-hospitalization services ... care, and rehabilitation. Notably, the authors found ... a few categories, while disparities were highest among the ...
... HealthDay Reporter , WEDNESDAY, Dec. 7 (HealthDay News) -- Multiple ... and work its way into the deep interior, according to ... system disease. The new findings, which could spur changes ... solidify a theory that,s emerged in recent years. This new ...
... in children or adults, often takes place even in ... obesity. Current methods to treat such overeating in ... eat, requiring them to track their food intake and ... such behavioral therapy techniques don,t work long term, according ...
Cached Medicine News:Health News:Women advised to avoid ZEN bust-enhancing supplements because of possible cancer risk 2Health News:Study sheds light on cancer burden in Australia 2Health News:Mayo Clinic: Obese patients with HER2-positive breast cancer may have worse outcomes 2Health News:Racial, ethnic and insurance disparities revealed in post-hospital care after trauma 2Health News:Racial, ethnic and insurance disparities revealed in post-hospital care after trauma 3Health News:MS May Take a Different Pathway Than Previously Thought 2Health News:MS May Take a Different Pathway Than Previously Thought 3Health News:New approach to management of overeating in children 2Health News:New approach to management of overeating in children 3
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
Practice-oriented ophthalmic laser systems for photodisruption....
... determining color vision abnormalities and testing color ... applied to many psychological and industrial color ... trays containing a total of 85 removable ... variation on one side and are numbered ...
Medicine Products: